The company operates in the agricultural sector, primarily trading seeds, fertilizers, and pesticides while providing advisory services and contract farming support to rural farmers.
The company operates in a highly fragmented and commoditized agri-input trading market with no evidence of proprietary technology or brand power, as reflected by extremely thin net margins of 0.6% and a heavy reliance on non-operating 'other income' for profitability.
Capital allocation is highly questionable, characterized by a massive proposed preferential issuance of 7 crore warrants that would dilute existing shareholders by over 1,000% to fund vague working capital needs despite having a very small existing business base.
The investment collapsed as the massive 1,000% equity dilution from the preferential warrant issuance effectively wiped out minority shareholders' claims on future earnings. The core trading business, already struggling with razor-thin 0.6% margins, failed to scale as the 'other income' that previously propped up the bottom line evaporated. Governance instability reached a breaking point when the revolving door of directors and key personnel left the company rudderless, and the lack of reconciled third-party balances eventually led to significant asset write-downs that the tiny capital base could not absorb.
RichFakir rates SC Agrotech Ltd's business quality as mediocre — 54/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, SC Agrotech Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on SC Agrotech Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of SC Agrotech Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →